2.19
+0.24(+12.31%)
Currency In USD
| Previous Close | 1.95 |
| Open | 1.95 |
| Day High | 2.22 |
| Day Low | 1.92 |
| 52-Week High | 2.22 |
| 52-Week Low | 0.77 |
| Volume | 4.11M |
| Average Volume | 2.57M |
| Market Cap | 218.51M |
| PE | -6.08 |
| EPS | -0.36 |
| Moving Average 50 Days | 1.62 |
| Moving Average 200 Days | 1.28 |
| Change | 0.24 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.04 as of June 30, 2025 at a share price of $2.165. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $738.91 as of June 30, 2025 at a share price of $2.165.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
GlobeNewswire Inc.
Jun 24, 2025 12:00 PM GMT
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indica
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
GlobeNewswire Inc.
Jun 05, 2025 12:45 PM GMT
New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This YearNEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: S
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025